A randomized, controlled non-inferiority trial comparing A(H1N1)pmd09 vaccine antigen, with and without AS03 adjuvant system, co-administered or sequentially administered with an inactivated trivalent seasonal influenza vaccine

BMC Infectious Diseases

David Vaughn¹  Ping Li¹  Scott Halperin⁴  Shelly McNeil⁴  Laurence Chu³  Louise Frenette²  Joanne M Langley⁴ 

[1] GlaxoSmithKline Vaccines, King of Prussia, Philadelphia, PA, USA;Q&T Research Inc, Sherbrooke, QC, Canada;Benchmark Research, Austin, TX, USA;Canadian Center for Vaccinology, IWK Health Centre, Capital District Health Authority and Dalhousie University, 5850 University Avenue, Halifax, NS, B3K 6R8, Canada

关键词: TIV;    Pandemic;    Influenza;    H1N1;    Co-administration;    AS03;    Adjuvant;   

Others  :  1159612
DOI  :  10.1186/1471-2334-12-279

 received in 2011-12-16, accepted in 2012-10-11,  发布年份 2012

【 摘 要 】

Background

At the time of the influenza A(H1N1)pmd09 pandemic it was not known if concurrent or sequential administration of seasonal trivalent influenza vaccine (TIV) with pandemic vaccine was preferred.

Methods

Immunogenicity and safety were assessed in 871 healthy subjects aged 19–40 years who were randomised into six groups to receive co-administration or sequential administration of TIV and two doses of A(H1N1)pmd09 vaccine (either unadjuvanted or adjuvanted with AS03, an α-tocopherol and squalene-based oil-in-water emulsion).

Results

Safety and immunogenicity data (by haemagglutination inhibition [HI] assay) after each dose and six months post-Dose 1 are reported here. Co-administration of A(H1N1)pmd09 vaccine with TIV reduced the HI immune responses to A(H1N1)pmd09 vaccine. However, serologic responses with both co-administration and sequential schedules met the European and US regulatory criteria for pandemic and seasonal influenza vaccines up to six months following the first vaccine dose. The AS03-adjuvanted formulation elicited higher immune responses at all time points. Prior administration or co-administration of A(H1N1)pmd09 vaccine did not affect immune responses to TIV.

Conclusions

Co-administration of TIV and A(H1N1)pmd09 vaccine negatively influenced A(H1N1)pmd09 vaccine immunogenicity but had no effect on TIV responses. The non-adjuvanted and adjuvanted vaccines demonstrated strong immune responses against all vaccine strains for up to six months following the first vaccine dose.

Trial registration

NCT00985673

【 授权许可】

   
2012 Langley et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Chowell G, et al.: Severe respiratory disease concurrent with the circulation of H1N1 influenza. N Engl J Med 2009, 361(7):674-679.
• [2]Centers for Disease Control and Prevention: Updated CDC Estimates of 2009 H1N1 Influenza Cases, Hospitalizations and Deaths in the United States, April 2009 – April 10, 2010. Morbidity and Mortality Weekly Report; 2010. (Published by CDC Atlanta)
• [3]National Institute of Allergy and Infectious Diseases: Bulletin: Early results: NIAID trial supports co-administration of 2009 H1N1 influenza vaccine and seasonal influenza vaccine. 2009. [cited 2009 October 9, 2009.]; Available from: http://www.niaid.nih.gov/news/newsreleases/2009/pages/h1n1plusseasonalvax.aspx webcite
• [4]Strategic Advisory Group of Experts. Global Alert and Response: WHO recommendations on pandemic (H1N1) 2009 vaccines. 2009. [cited 2009 10 October 2009]; Available from: WHO recommendations on pandemic (H1N1) 2009 vaccines
• [5]Peeters S, et al.: Safety and immunogenicity of an AS03-adjuvanted A(H1N1)pmd09 vaccine administered simultaneously or sequentially with a seasonal trivalent vaccine in adults 61 years or older: Data from two multicentre randomised trials. Vaccine 2012, 30:6483-6491.
• [6]Vajo Z, et al.: Safety and immunogenicity of a 2009 pandemic influenza A H1N1 vaccine when administered alone or simultaneously with the seasonal influenza vaccine for the 2009–10 influenza season: a multicentre, randomised controlled trial. Lancet 2010, 375(9708):49-55.
• [7]Gasparini R, et al.: Impact of prior or concomitant seasonal influenza vaccination on MF59-adjuvanted H1N1v vaccine (Focetria) in adult and elderly subjects. Int J Clin Pract 2010, 64(4):432-438.
• [8]Global Advisory and Safety Committee World Health Oragnization: Thiomersal and vaccines: questions and answers. 2006. [cited 2011 Oct 3]; Available from: http://www.who.int/vaccine_safety/topics/thiomersal/questions/en/index.html webcite
• [9]Lee VJ, et al.: Inactivated trivalent seasonal influenza vaccine induces limited cross-reactive neutralizing antibody responses against 2009 pandemic and 1934 PR8 H1N1 strains. Vaccine 2010, 28(42):6852-6857.
• [10]Xie H, et al.: Immunogenicity and cross-reactivity of 2009–2010 inactivated seasonal influenza vaccine in US adults and elderly. PLoS One 2011, 6(1):e16650.
• [11]Manzoli L, et al.: Meta-analysis of the immunogenicity and tolerability of pandemic influenza A 2009 (H1N1) vaccines. PLoS One 2011, 6(9):e24384.
• [12]Roman F, et al.: AS03(A)-Adjuvanted influenza A (H1N1) 2009 vaccine for adults up to 85 years of age. Clin Infect Dis 2010, 51(6):668-677.
• [13]Hehme NW, et al.: Ten years of experience with the trivalent split-influenza vaccine, Fluarix(TM). Clin Drug Invest 2002, 22:751-769.
• [14]European Committee for Proprietary Medicinal Products (CHMP): European Agency for the Evaluation of Medicinal Products. In Guideline on influenza vaccine prepared from viruses with the potential to cause a pandemic and intended for use outside of the core dossier context (EMEA/CHMP/VWP/263499/2006). London: European Medicines Agency; 2007:11.
• [15]U.S. Department of Health and Human Services Food and Drug Administration Center for Biologics Evaluation and Research: Guidance for industry: Clinical data needed to support the licensure of seasonal inactivated influenza vaccines. FDA. 2007. Available from: http://www.fda.gov/downloads/biologicsbloodvaccines/guidancecomplianceregulatoryinformation/quidances/vaccines/ucm091990.pdf webcite